161 related articles for article (PubMed ID: 1518264)
1. [Clinical experiences with adrenaline as therapy and prevention of E. coli-L-asparaginase-induced anaphylaxis].
Schwinger W; Urban C; Lackner H
Klin Padiatr; 1992; 204(4):274-6. PubMed ID: 1518264
[TBL] [Abstract][Full Text] [Related]
2. [Long-term infusion of L-asparaginase--an alternative to intramuscular injection?].
Rodriguez T; Baumgarten E; Fengler R; Soumpasis D; Henze G
Klin Padiatr; 1995; 207(4):207-10. PubMed ID: 7564153
[TBL] [Abstract][Full Text] [Related]
3. [Comparative pharmacokinetic study of two different ways of using L-asparaginase as the main drug in combination chemotherapy].
Wang Y; Jiang H; Xie X
Zhonghua Xue Ye Xue Za Zhi; 1999 Nov; 20(11):589-91. PubMed ID: 11721378
[TBL] [Abstract][Full Text] [Related]
4. Antimetabolite-based therapy in childhood T-cell acute lymphoblastic leukemia: a report of POG study 9296.
Winter SS; Holdsworth MT; Devidas M; Raisch DW; Chauvenet A; Ravindranath Y; Ducore JM; Amylon MD
Pediatr Blood Cancer; 2006 Feb; 46(2):179-86. PubMed ID: 16007607
[TBL] [Abstract][Full Text] [Related]
5. Increased thrombin generation during fibrinogen and platelet recovery as an explanation for hypercoagulability in children with L-asparaginase therapy for ALL or NHL: a preliminary report.
Korte W; Feldges A; Baumgartner C; Ullmann S; Niederer V; Schmid L
Klin Padiatr; 1994; 206(4):331-3. PubMed ID: 7967434
[TBL] [Abstract][Full Text] [Related]
6. Effect of glucocorticoids, E. coli- and Erwinia L-asparaginase on hemostatic proteins in children with acute lymphoblastic leukemia.
Mall V; Thomas KB; Sauter S; Niemeyer CM; Sutor AH
Klin Padiatr; 1999; 211(4):205-10. PubMed ID: 10472551
[TBL] [Abstract][Full Text] [Related]
7. Characterization of hypertriglyceridemia induced by L-asparaginase therapy for acute lymphoblastic leukemia and malignant lymphoma.
Tozuka M; Yamauchi K; Hidaka H; Nakabayashi T; Okumura N; Katsuyama T
Ann Clin Lab Sci; 1997; 27(5):351-7. PubMed ID: 9303174
[TBL] [Abstract][Full Text] [Related]
8. Erwinia- and E. coli-derived L-asparaginase have similar effects on hemostasis. Pilot study in 10 patients with acute lymphoblastic leukemia.
Castaman G; Rodeghiero F
Haematologica; 1993; 78(6 Suppl 2):57-60. PubMed ID: 8039761
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic drug monitoring of asparaginase in the ALL-BFM 2000 protocol between 2000 and 2007.
Schrey D; Borghorst S; Lanvers-Kaminsky C; Hempel G; Gerss J; Möricke A; Schrappe M; Boos J
Pediatr Blood Cancer; 2010 Jul; 54(7):952-8. PubMed ID: 20108339
[TBL] [Abstract][Full Text] [Related]
10. Successful management of severe L-asparaginase-associated pancreatitis by continuous regional arterial infusion of protease inhibitor and antibiotic.
Morimoto A; Imamura T; Ishii R; Nakabayashi Y; Nakatani T; Sakagami J; Yamagami T
Cancer; 2008 Sep; 113(6):1362-9. PubMed ID: 18661511
[TBL] [Abstract][Full Text] [Related]
11. [L-asparaginase-induced hyperlipidemia in a case of acute lymphoblastic leukemia].
Konya H; Tamura S; Miyazaki E; Inoue N; Okamoto T; Takemoto Y; Kohsaki M; Kanemaru A; Kakishita E
Rinsho Ketsueki; 1991 Mar; 32(3):250-4. PubMed ID: 2041167
[TBL] [Abstract][Full Text] [Related]
12. Diabetes mellitus and pancreatitis as a complication of L-asparaginase therapy.
Charan VD; Desai N; Singh AP; Choudhry VP
Indian Pediatr; 1993 Jun; 30(6):809-10. PubMed ID: 8132268
[No Abstract] [Full Text] [Related]
13. Retherapy using L-asparaginase with octreotide in a patient recovering from L-asparaginase-induced pancreatitis.
Suzuki M; Takata O; Sakaguchi S; Fujimura J; Saito M; Shimizu T
Exp Hematol; 2008 Mar; 36(3):253-4. PubMed ID: 18279714
[No Abstract] [Full Text] [Related]
14. Diabetic ketoacidosis with L-asparaginase therapy.
Mondal R; Nandi M; Tiwari A; Chakravorti S
Indian Pediatr; 2011 Sep; 48(9):735-6. PubMed ID: 21992909
[TBL] [Abstract][Full Text] [Related]
15. [Research on the pharmacokinetics and pharmacodynamics of L-asparaginase during its treatment of childhood acute lymphoblastic leukemia].
Chen FX; Cui YQ; Wu ZL; Ye TZ; Lai YH; Zou YW; Lu CY; Guan JM; Wei FG; Zhang H
Zhonghua Xue Ye Xue Za Zhi; 2005 Feb; 26(2):100-2. PubMed ID: 15921627
[TBL] [Abstract][Full Text] [Related]
16. Minimal residual disease (MRD) measurement as a tool to compare the efficacy of chemotherapeutic drug regimens using Escherichia Coli-asparaginase or Erwinia-asparaginase in childhood acute lymphoblastic leukemia (ALL).
Kwok CS; Kham SK; Ariffin H; Lin HP; Quah TC; Yeoh AE
Pediatr Blood Cancer; 2006 Sep; 47(3):299-304. PubMed ID: 16302217
[TBL] [Abstract][Full Text] [Related]
17. [Comparative evaluation of the clinical effectiveness of 3 preparations of E. coli L-asparaginase].
Kondrat'eva NA
Antibiotiki; 1984 Jul; 29(7):527-31. PubMed ID: 6385831
[TBL] [Abstract][Full Text] [Related]
18. Hyperglycemia, ketoacidosis and other complications of L-asparaginase in children with acute lymphoblastic leukemia.
Cetin M; Yetgin S; Kara A; Tuncer AM; Günay M; Gümrük F; Gürgey A
J Med; 1994; 25(3-4):219-29. PubMed ID: 7996065
[TBL] [Abstract][Full Text] [Related]
19. Transient hyperammonemia due to L-asparaginase therapy in children with acute lymphoblastic leukemia or non-Hodgkin lymphoma.
Jörck C; Kiess W; Weigel JF; Mütze U; Bierbach U; Beblo S
Pediatr Hematol Oncol; 2011 Feb; 28(1):3-9. PubMed ID: 20615069
[TBL] [Abstract][Full Text] [Related]
20. Asparaginase-induced acute parotitis: an uncommon and self-limiting complication.
Chan GC; Chiang AK; Ha SY; Lau YL; Ong JB; Lee AC
Med Pediatr Oncol; 2002 Jul; 39(1):73-4. PubMed ID: 12116090
[No Abstract] [Full Text] [Related]
[Next] [New Search]
